NAD Therapy for Improving Memory and Brain Blood Flow in Older Adults With Mild Cognitive Impairment

What Was Tested

In this phase 1, phase 2 trial, researchers set out to test NAD+.

It had two arms (groups): Placebo (placebo comparator) and Nicotinamide Riboside (experimental).

Placebo.

The registry classes the interventions as drug and other.

Who Took Part

Enrollment: 64 actual participants took part.

It was open to people of any sex aged from 60 years up to 90 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Cognitive function scores consistent with amnestic mild cognitive impairment based on pre-screening evaluation;. Age 60-90 years;. MMSE score \>24 at time of initial consent;.

The full record lists 3 inclusion and 12 exclusion criteria; among the exclusions: major psychiatric disorder (e.g. schizophrenia, bipolar disorder, major depression within past two years);; neurological or autoimmune conditions affecting cognition (e.g. parkinson's disease, epilepsy, multiple sclerosis, mild or severe traumatic brain injury, large vessel infarct);; concussion within last 2 years and ≥ 3 lifetime concussions;.

How the Study Was Run

Design: randomized, parallel-group and double-blind.

Because people in this NAD+ study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Blinding on both sides kept the participants and researchers unaware of who received NAD+.

Those kept unaware of assignments: participant and investigator.

It started in 2019-03-20 with completion listed for 2024-01-08.

It ran at 1 site in United States.

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Cognitive Scores at Baseline and Week 12 (time frame: baseline and 12 weeks).

It also tracked 4 secondary outcomes, for example Cerebrovascular Reactivity at Baseline and 12 Weeks, Total Brain Blood Flow at Baseline and 12 Weeks, Aortic Stiffness at Baseline and 12 Weeks and Blood Pressure at Baseline and 12 Weeks.

What This Means in Plain Language

Put simply, this is a phase 1, phase 2, randomized trial of NAD+ in 64 people.

The trial is marked completed; results are posted on the registry, and this page does not restate them.

More context: the NAD+ compound page, all human trials.